Keytruda (pembrolizumab) is a biologic drug used to treat various types of cancer, including melanoma, non-small cell lung cancer, head and neck cancer, and others. According to Drug Patent Watch [1], Keytruda's cost per treatment course is approximately $30,000-$40,000. However, the actual cost of treatment can vary depending on several factors, including the patient's insurance coverage, the dosage prescribed, and the duration of treatment.

In terms of financial support, Merck, the manufacturer of Keytruda, offers a program called "Key+You" [2], which provides financial assistance to eligible patients who cannot afford the cost of treatment. This program offers co-pay assistance, free drug programs, and other financial support options.

When comparing Keytruda's cost to other treatments, it is essential to consider the drug's effectiveness and the overall cost of cancer treatment. According to a study published in the Journal of Oncology Pharmacy Practice [3], Keytruda's cost-effectiveness is comparable to other cancer treatments, such as nivolumab and ipilimumab. However, the study notes that the cost of cancer treatment, in general, is increasing, and the high cost of cancer drugs can pose a significant financial burden on patients and their families.

In conclusion, Keytruda's cost per treatment course is approximately $30,000-$40,000, and Merck offers financial assistance to eligible patients who cannot afford the cost of treatment. Keytruda's cost-effectiveness is comparable to other cancer treatments, but the high cost of cancer drugs can pose a significant financial burden on patients and their families.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.keytruda.com/financial-support/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481296/